

晚期肺癌肝转移的综合治疗进展

《现代肿瘤医学》[ISSN:1672-4992/CN:61-1415/R] 期数: 2019年12期 页码: 2200-2203 栏目: 综述 出版日期: 2019-05-08

Title: Progress in comprehensive treatment of liver metastasis in advanced lung cancer

作者: 许田慧; 刘宝刚

哈尔滨医科大学附属肿瘤医院呼吸内科, 黑龙江 哈尔滨 150086

Author(s): Xu Tianhui; Liu Baogang

The Department of Respiratory Medicine, Harbin Medical University Cancer Hospital, Heilongjiang Harbin 150086, China.

关键词: 肺癌; 肝转移; 综合治疗

Keywords: lung cancer; liver metastasis; comprehensive treatment

分类号: R734.2

DOI: 10.3969/j.issn.1672-4992.2019.12.042

文献标识码: A

摘要: 肝脏是肺癌血液转移常见的部位。存在肝转移患者病情迅速发展,多在7个月内死亡。因此,采取积极有效的治疗措施,对进一步改善晚期肺癌患者的预后具有极其重要的意义。目前,针对肺癌肝转移的治疗还没有达成统一的治疗计划,常见的治疗方法有手术治疗、全身化疗、介入治疗、射频消融治疗、立体定向放疗、靶向治疗、免疫治疗等。对此,我们就近年来肺癌肝转移的综合治疗进展作一综述。

Abstract: The liver is a common site of blood metastasis of lung cancer. There is a rapid development of liver metastases (LM), with more than 7 months of death. Therefore, taking active and effective treatment measures is of great significance to further improve the prognosis of patients with advanced lung cancer. At present, there is no unified treatment plan for the treatment of liver metastases from lung cancer. Common treatment methods include surgical treatment, systemic chemotherapy, interventional therapy, radiofrequency ablation therapy, stereotactic radiotherapy, targeted therapy, and immunization therapy. In this regard, we reviewed the progress in the comprehensive treatment of liver metastases from lung cancer in recent years.

参考文献/REFERENCES

- [1] Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015 [J]. *A Cancer Journal for Clinicians*, 2016, 66(2): 115-132.
- [2] Ileana E, Greillier L, Moutardier V, et al. Surgical resection of liver non-small cell lung cancer metastasis: A dual weapon [J]. *Lung Cancer*, 2010, 70(2): 221-222.
- [3] Brouquet A, Vauthey JN, Contreras CM, et al. Improved survival after resection of liver and lung colorectal metastases compared with liver-only metastases: A study of 112 patients with limited lung metastatic disease [J]. *J Am Coll Surg*, 2011, 213(1): 62-69.
- [4] Nagashima A, Abe Y, Yamada S, et al. Long-term survival after surgical resection of liver metastasis from lung cancer [J]. *Kyobu Geka the Japanese Journal of Thoracic Su*, 2010, 63(3): 216-219.
- [5] Klement RJ, Guckenberger M, Alheid H, et al. Stereotactic body radiotherapy for oligo-metastatic liver disease-influence of pre-treatment chemotherapy and histology on local tumor control [J]. *Radiother Oncol*, 2017, 123(2): 227-233.
- [6] Milano MT, Katz AW, Schell MC, et al. Descriptive analysis of oligometastatic lesions treated with curative-intent stereotactic body radiotherapy [J]. *Int J Radiat Oncol Biol Phys*, 2008, 72(5): 1516-1522.
- [7] Kanthi, Rekha, Badipatla, et al. Lung cancer metastasis to the gastrointestinal system: An enigmatic occurrence [J]. *World Journal of Gastrointestinal Oncology*, 2017, 9(3): 129-134.
- [8] Shaverdian N, Lisberg AE, Bornazyan K, et al. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: A secondary analysis of the KEYNOTE-001 phase 1 trial [J]. *Lancet Oncol* 2017, 18: 895-903.
- [9] Lin SZ, Xu Qian, Wu JY, et al. Ultrasound-guided percutaneous radiofrequency ablation for malignant liver metastases [J]. *Chinese Journal of Interventional Imaging and Therapy*, 2018, 15(1): 29-32. [林淑芝, 徐倩, 武金玉, 等. 超声引导下经皮射频消融治疗恶性肿瘤肝转移 [J]. *中国介入影像与治疗学*, 2018, 15(1): 29-32.]
- [10] Tseng SE, Chiou YY, Lee YC, et al. Number of liver metastatic nodules affects treatment options for pulmonary adenocarcinoma patients with liver metastases [J]. *Lung Cancer*, 2014, 86(2): 225-230.

- [11] Lorentzen T, Skjoldbye BO, Nolsoe CP. Microwave ablation of liver metastases guided by contrast-enhanced ultrasound: Experience with 125 metastases in 39 patients [J]. *Ultraschall Med*, 2011, 32(5):492-496.
- [12] Shibata T, Niinobu T, Ogata N, et al. Microwave coagulation therapy for multiple hepatic metastases from colorectal carcinoma [J]. *Cancer*, 2000, 89(2):276-284.
- [13] Ai DM, Xu JX, Liu CJ, et al. Microwave ablation treatment of liver metastatic carcinoma clinical efficacy and related factors affecting survival rate [J]. *Cancer Progression*, 2017, 15(6):667-669. [艾冬梅, 许军星, 刘成军, 等. 微波消融治疗肝转移癌临床疗效及影响生存率的相关因素研究 [J]. *癌症进展*, 2017, 15(6):667-669.]
- [14] Wang S, Wei YD, Zhao Z, et al. Risk factors of liver metastasis in non-small cell lung cancer and comparison of different therapies [J]. *Chinese Journal of Disease Control*, 2016, 20(9):936-939. [王森, 魏元东, 赵智, 等. 非小细胞肺癌肝转移的危险因素分析及不同疗法的比较 [J]. *中华疾病控制杂志*, 2016, 20(9):936-939.]
- [15] Chen L, Huang P, Zhang XJ, et al. Efficacy and safety evaluation of irinotecan plus lobaplatin in patients with small cell lung cancer liver metastases who failed chemotherapy with etoposide regimen [J]. *Hebei Medicine*, 2016, 38(20):3098-3100. [陈珑, 黄平, 张相杰, 等. 伊立替康联合洛铂对依托泊苷方案化疗失败小细胞肺癌肝转移患者的疗效及安全性评价 [J]. *河北医药*, 2016, 38(20):3098-3100.]
- [16] Heist RS, Guarino MJ, Masters G. Therapy of advanced non-small-cell lung cancer with an SN-38-anti-trop-2 drug conjugate, sacituzumab govitecan [J]. *Clin Oncol*, 2017, 35(24):2790-2797.
- [17] Zhang CS, Liu XL. Therapeutic effect of intravenous chemotherapy combined with percutaneous ethanol injection for hepatic metastasis [J]. *Modern Oncology*, 2016, 24(18):2906-2909. [张诚胜, 刘先领. 静脉化疗联合经皮穿刺无水酒精肝转移瘤内注射治疗肺癌伴肝转移的疗效 [J]. *现代肿瘤医学*, 2016, 24(18):2906-2909.]
- [18] Gao BY, Liu Y, Xia LP, et al. Effect of hepatic arterial infusion chemoembolization combined with microwave ablation on advanced liver cancer [J]. *Journal of Hainan Medical University*, 2012, 18(9):1228-1231. [高炳玉, 刘玉, 夏立平, 等. 肝动脉灌注化疗栓塞联合微波消融治疗中晚期肝癌的疗效观察 [J]. *海南医学院学报*, 2012, 18(9):1228-1231.]
- [19] Liu XZ, Li H, Wang X, et al. Clinical value of hepatic arterial chemoembolization combined with percutaneous microwave ablation for liver metastasis of lung cancer [J]. *Medical Equipment*, 2016, 29(14):16-17. [刘翔鹭, 李辉, 王希, 等. 肝动脉化疗栓塞联合经皮穿刺微波消融治疗肺癌肝转移的临床价值探究 [J]. *医疗装备*, 2016, 29(14):16-17.]
- [20] Xue MY, Zhou ZM. Therapeutic effect and safety of dual interventional treatment for lung cancer with hepatic metastasis [J]. *Chinese Hepatology*, 2017, 22(11):1038-1041. [薛明月, 周志明. 双重介入治疗肺癌合并肝转移的疗效和安全性探讨 [J]. *肝脏*, 2017, 22(11):1038-1041.]
- [21] Tseng SE, Chiou YY, Lee YC, et al. Number of liver metastatic nodules affects treatment options for pulmonary adenocarcinoma patients with liver metastases [J]. *Lung Cancer*, 2014, 86(2):225-230.
- [22] Yu HA, Sima CS, Huang J, et al. Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors [J]. *Thorac Oncol*, 2013, 8(3):346-351.
- [23] Castanon E, Rolfo C, Vinal D, et al. Impact of epidermal growth factor receptor (EGFR) activating mutations and their targeted treatment in the prognosis of stage IV non-small cell lung cancer (NSCLC) patients harboring liver metastasis [J]. *Journal of Translational Medicine*, 2015, 13(1):257.
- [24] Zhu ZY, Chai Y. Complete remission of liver metastasis in a lung cancer patient with epidermal growth factor mutation achieved with Icotinib [J]. *Thoracic Cancer*, 2016, 7(6):681-683.
- [25] Liu XL, Ji W, Li L, et al. Treatment of lung adenocarcinoma with erlotinib hydrochloride tablets, post-drug chemotherapy and bevacizumab injection: a case report and review of literature [J]. *Journal of Jilin University (Medicine Edition)*, 2017, 43(5):1019-1024. [刘相良, 纪伟, 李理, 等. 盐酸厄洛替尼片及耐药后化疗联合贝伐珠单抗注射液治疗肺腺癌1例报告并文献复习 [J]. *吉林大学学报(医学版)*, 2017, 43(5):1019-1024.]
- [26] Tournoy KG, Thomeer M, Germonpré P, et al. Does nivolumab for progressed metastatic lung cancer fulfill its promises? An efficacy and safety analysis in 20 general hospitals [J]. *Lung Cancer*, 2018, 115:49-55.
- [27] Ricciuti B, Metro G, Baglivo S, et al. Long-lasting response to nivolumab and immune-related adverse events in a nonsquamous metastatic non-small cell lung cancer patient [J]. *Journal of Thoracic Oncology*, 2017, 12(5):51-55.
- [28] Vokes EE, Ready E, Felip E, et al. Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases [J]. *Annals of Oncology*, 2018, 44(1):12-21.
- [29] Funazo T, Nomizo T, Kim YH. Liver metastasis is associated with poor progression-free survival in patients with non-small cell lung cancer treated with nivolumab [J]. *Thorac Oncol*, 2017, 12(9):140-141.

备注/Memo: -

更新日期/Last Update: 1900-01-01